Patents And Health Under Discussion At WIPO This Week: What Role For The UN IP Agency? 12/12/2017 by Catherine Saez, Intellectual Property Watch Leave a Comment Patents are often involved in public health policy discussions, and are considered by some as playing a major role in the escalating prices of new medicines, creating access issues. The World Intellectual Property Organization committee on patent law this week is discussing the issue and is holding information sessions by the Medicines Patent Pool, World Health Organization, and the World Trade Organization.
Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 by Intellectual Property Watch Leave a Comment The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications.
EPO Study Shows Rise In Patents On Next Generation Technologies 11/12/2017 by Intellectual Property Watch Leave a Comment The European Patent Office (EPO) today announced a study that showed “European patent applications related to smart connected objects are rising rapidly, achieving a growth rate of 54% in the last three years.”
Special Feature: 5G And Standard Essential Patents In The US 08/12/2017 by William New, Intellectual Property Watch Leave a Comment NEW YORK — A panel at the recent IP Dealmakers Forum including a US Federal Trade Commission official, a former US judge on a key patent case, and a telecommunications industry licensing expert walked through issues and prospects for the coming of the 5G next generation wireless technology. Views differed on points but panellists agreed that changes are needed to the system for standard-essential patents, including a bigger role for standard-setting organisations. Below is an in-depth account of the discussion. The discussion also included the latest state-of-play at the FTC, which currently has its lowest number of commissioners ever.
Global Patents Soar Again As China Tops Patent, Trademark, Design Filings 06/12/2017 by Peter Kenny for Intellectual Property Watch Leave a Comment Innovators around the world filed 3.1 million patent applications in 2016, up 8.3 percent in a seventh straight yearly increase, WIPO’s annual World Intellectual Property Indicators (WIPI) report shows. The report, WIPO’s annual report, released at the United Nations in Geneva today, showed China topping patent, trademark and design filings in 2016.
Breeders Group CIOPORA Calls For New Plant Varieties To Be Patentable 23/11/2017 by Catherine Saez, Intellectual Property Watch Leave a Comment A new “position paper” by a plant breeders industry group revives the argument that plant-related inventions should be patentable. New plant breeding techniques modifying the plant genome are not essentially biological processes, thus should be patentable, the paper says. The group also calls for a worldwide harmonised research exemption on plant variety rights and patents for the purpose of improving the invention.
Special Report: A Look Behind Hepatitis C Patent Challenges Worldwide 15/11/2017 by Tatum Anderson for Intellectual Property Watch 2 Comments A case at the High Court in India set for 15 December could decide whether a patent on some of the most important drugs to fight hepatitis C should be removed. It is one of many attempts to challenge patents on hepatitis C drugs in various countries around the world and serves as an opportunity to learn more about the group leading the legal case.
USPTO’s Revised Patent Fee Schedule Raises Price Of IPR Process 14/11/2017 by Intellectual Property Watch 1 Comment The United States Patent and Trademark Office (USPTO) today issued changes to some patent fees, including increases in certain areas, including the cost of using the inter partes review process. Following feedback from users, the office went with some proposed increases, while keeping others at existing levels despite proposals to increase them, it said.
US Congress Members Signal Move To Block Allergan Patent Deal With Tribe 14/11/2017 by William New, Intellectual Property Watch Leave a Comment Members of a US congressional subcommittee on intellectual property held a hearing last week that appeared aimed at finding ways to stop companies from “renting” the sovereignty of Native American tribes in order to avoid a process that can lead to the invalidation of patents. Elected officials called a deal between Allergan pharmaceutical company and a northeastern tribe a “sham” and a “mockery”, and signalled the start of the legislative procedure to prevent such deals.
Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 by Intellectual Property Watch 11 Comments A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment.